Mediaboss Marketing

(PRWEB) December 10, 2013

bestwebdesignagencies.in has announced the ten best Joomla web development companies in India for the month of December 2013. The rankings consist of web design service providers which have years of experience in professional quality solutions. The rankings are produced through a methodical examination process which involves the inspection and testing of top Joomla web development companies to identify which are most effective at supplying their solutions. While there are thousands of web design companies supplying solutions the rankings are used to feature the absolute best.

To view the ratings of the best Joomla development consultants in India click here.

The bestwebdesignagencies.in independent research team spends time researching Joomla development firms in India by taking a systematic look at key strengths and competitive advantages of performing web development firms. The listings are produced through the use of a set of evaluation verticals. The five verticals used to benchmark and compare Joomla development firms include design quality, future compatibility, customer support, development quality, and service. Web development firms are put to the test to ensure the best firms are included to assist businesses in selecting the absolute best Joomla development firms to meet their specific needs.

ABOUT bestwebdesignagencies.in

bestwebdesignagencies.in is a producer of web development evaluations in India. The central ambition of bestwebdesignagencies.in is to uncover and publish those individuals or companies supplying best web development solutions available. Joomla web development companies are put through a thorough investigation to ensure the rankings contain the absolute best companies the web development industry has to offer.

Joomla development services interested in being evaluated and named can visit:

http://bestwebdesignagencies.news-prs.com/in/apply-for-rankings

More here:
10 Best Joomla Development Companies in India Released by bestwebdesignagencies.in for December 2013

PRESS RELEASE: Biotest AG: Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone

DGAP-News: Biotest AG / Key word(s): Study Biotest AG: Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone

10.12.2013 / 01:30

=--------------------------------------------------------------------

PRESS RELEASE

Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone

- Efficacy and tolerability data from combination therapy study 983 presented at 55th annual conference of the American Society of Hematology (ASH)

- Good tolerability of combination therapy with indatuximab ravtansine (BT-062) at a dosage up to 100 mg/m2

- Clinical benefit seen in all evaluable patients

- Complete response observed in individual patients

More:
PRESS RELEASE: Biotest AG: Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good ...

PRESS RELEASE: Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim

DGAP-News: Evotec AG / Key word(s): Miscellaneous Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim

10.12.2013 / 07:29

=--------------------------------------------------------------------

Hamburg, Germany - 10 December 2013: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of EUR 4.0 m to Evotec. The milestone was for the transition of an oncology molecule into pre-clinical development.

Dr Mario Polywka, Chief Operating Officer of Evotec commented: 'This is the twenty-first milestone achieved as part of our alliance with Boehringer Ingelheim and represents a third oncology compound transitioning into pre-clinical development of which one is already in Phase I clinical trials. Our collaboration with Boehringer Ingelheim continues to support Evotec's overall strategy of building up a pipeline of assets of which we have interest in future upside.'

ABOUT THE EVOTEC & BOEHRINGER INGELHEIM ALLIANCE In 2004, Evotec entered into a multi-year, multi-target drug discovery alliance with Boehringer Ingelheim to jointly identify and develop pre-clinical development candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases. In 2009, the collaboration was extended for an additional four years and the scope expanded to include oncology targets. Under the terms of the agreement, Boehringer Ingelheim has full ownership and global responsibility for clinical development, manufacturing and commercialisation of the compounds identified. In return, Evotec receives ongoing research payments and pre-clinical milestones. Furthermore, the contract provides substantial long-term upside for Evotec through potential payments for successful milestone achievements during clinical development and royalties when new drugs reach the market.

ABOUT EVOTEC AG Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to http://www.evotec.com.

FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG: Gabriele Hansen, Head of Corporate Communications, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

Follow this link:
PRESS RELEASE: Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim

Mario Party 2 - Censorship - Part 7
It #39;s for your own good, I promise. Game: Mario Party 2 System: Nintendo 64 Players in controller port order: Loran (Yoshi) Kronsvorder (Wario) Lucinius (Luig...

By: OurFinalForm

See the original post here:
Mario Party 2 - Censorship - Part 7 - Video

By Victor Davidoff

Published: December 9, 2013 (Issue # 1789)

Schoolchildren in the city of Krasnodar will not be able to watch a puppet theater performance of Mozart's opera "The Magic Flute" this year. Bureaucrats at the Federal Mass Media Inspection Service put an 18+ label on the show. The reason: In the opera, one of the heroines wants to kill herself.

Age restrictions on access to information, including Internet sites, have been in place for more than a year in the country. But until now they had not been applied to classical works of literature and art. Soon this might change. On Dec. 4, the Federal Mass Media Inspection Service presented a project called "The Concept of Informational Security for Children." Among its stipulations is a ban that would keep minors from watching on the Internet classical works of art that include images of the nude body in any form, and anything that might be considered erotic.

Censorship would also extend to works of literature in which the characters use alcohol and drugs or commit crimes, or in works where there are "statements destructive to the social institution of the family."

A more radical proposal in the project forbids "the depiction or description of mishaps, accidents or catastrophes" in television and radio news shows before 9 p.m. If this becomes law, daytime news shows will revert to the Soviet standard of "all day, all good news."

Teenage morality has become the idee fixe of lawmakers and bureaucrats for the last year or so. They passed a homophobic law forbidding "homosexual propaganda" supposedly to "protect children" and are using the same argument to step up censorship on the Internet.

Censorship on the Russian Internet has existed for a long time and is handled by several agencies: the Interior Ministry, the Federal Security Service, the Federal Drug Control Service and even the Federal Consumer Protection Service. These agencies draw up a list of sites to be blocked by the providers. These lists contain thousands of sites and pages.

A glance at the list of "extremist" materials on the Justice Ministry site shows that "care for children" is a smokescreen for politics. You can find just about anything on the list, from "Mein Kampf" and videos of Islamic fundamentalists to sites of the Jehovah's Witnesses, unregistered political parties and opposition blogs.

Continue reading here:
Internet Censorship Is Getting Worse